DexCom (DXCM) 10-K Summary — Year Ended Dec 31, 2025
DexCom reported annual revenue growth, with operating income and net income positive. Operating cash flow provided a key source of liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
DexCom reported annual revenue growth, with operating income and net income positive. Operating cash flow provided a key source of liquidity.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$4.7B
Revenue reported for the fiscal year.
Operating income
$911.8M
Income from operations reported for the year.
Net income
$836.3M
Net income reported for the year.
Operating cash flow
$1.4B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $2.9B | +18.8% |
| Dec 31, 2023 | $3.6B | +24.5% |
| Dec 31, 2024 | $4B | +11.3% |
| Dec 31, 2025 | $4.7B | +15.6% |
Business overview
The company develops, manufactures, and commercializes approved products through research and development and selling activities. It operates in a competitive market with a focus on innovation and regulatory approval.
Financial performance
Revenue increased year over year, reflecting consistent growth. Operating income and net income remained positive, while operating cash flow strengthened the company's financial position.
Material risks
The company's investments are subject to credit, liquidity, and market risks, which may be amplified by economic conditions. Future capital requirements depend on factors such as international expansion, scaling operations, and research and development success.
Liquidity and capital
Primary liquidity sources include cash, cash equivalents, marketable securities, operating cash flow, senior convertible notes, and a credit facility. Cash is used for research and development, sales and marketing, capital expenditures, acquisitions, and debt service.
What to watch
The evolution of international expansion and its impact on revenue from approved products.